Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 5INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 48Myeloid 25Lymphoid 7Breast 6Tumor-Agnostic 3Genitourinary 3Plasma cell 2Thoracic 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 3

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Dasatinib × Tumor-Agnostic × Clear all
NCT00099606 2011-04-19

Phase I (PH I) Mad Refractory Solid Tumor Study

Bristol-Myers Squibb

Phase 1 Completed
60 enrolled
Tumor-Agnostic

Neoplasms

NCT00162214 2011-04-14

Study of Dasatinib in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1 Terminated
60 enrolled
Tumor-Agnostic

Neoplasms

NCT00339144 2010-12-15

Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
16 enrolled 29 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡